Cargando…
gC1qR/HABP1/p32 Is a Potential New Therapeutic Target Against Mesothelioma
Mesothelioma is an aggressive cancer of the serous membranes with poor prognosis despite combination therapy consisting of surgery, radiotherapy, and platinum-based chemotherapy. Targeted therapies, including immunotherapies, have reported limited success, suggesting the need for additional therapeu...
Autores principales: | Peerschke, Ellinor, Stier, Kenneth, Li, Xiaoyu, Kandov, Evelyn, de Stanchina, Elisa, Chang, Qing, Xiong, Yuquan, Manova-Todorova, Katia, Fan, Ning, Barlas, Afsar, Ghebrehiwet, Berhane, Adusumilli, Prasad S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7435067/ https://www.ncbi.nlm.nih.gov/pubmed/32903438 http://dx.doi.org/10.3389/fonc.2020.01413 |
Ejemplares similares
-
Anti gC1qR/p32/HABP1 Antibody Therapy Decreases Tumor Growth in an Orthotopic Murine Xenotransplant Model of Triple Negative Breast Cancer
por: Peerschke, Ellinor I., et al.
Publicado: (2020) -
Globular C1q Receptor (gC1qR/p32/HABP1) Is Overexpressed in Malignant Pleural Mesothelioma and Is Associated With Increased Survival in Surgical Patients Treated With Chemotherapy
por: Li, Xiaoyu, et al.
Publicado: (2019) -
Loss of Mucosal p32/gC1qR/HABP1 Triggers Energy Deficiency and Impairs Goblet Cell Differentiation in Ulcerative Colitis
por: Sünderhauf, Annika, et al.
Publicado: (2021) -
Complement protein C1q stimulates hyaluronic acid degradation via gC1qR/HABP1/p32 in malignant pleural mesothelioma
por: Balduit, Andrea, et al.
Publicado: (2023) -
Soluble gC1qR in Blood and Body Fluids: Examination in a Pancreatic Cancer Patient Cohort
por: Peerschke, Ellinor IB, et al.
Publicado: (2015)